Alpha 2.0
Login Register
» Articles » PMID: 38483403

State Coverage and Reimbursement of Antiobesity Medications in Medicaid

Overview
Journal JAMA
Publisher American Medical Association
Specialty General Medicine
Date 2024 Mar 14
PMID 38483403
Authors
Benjamin Y Liu
Benjamin N Rome
Affiliations
Soon will be listed here.
Citing Articles

Comparing clinical practice habits among obesity medicine physicians by patient, physician and clinic factors.

Rajagopal S, Wickham 3rd E, Reid T, Brittan D, Korner J, Gudzune K Obes Pillars. 2025; 13:100157.

PMID: 39906906 PMC: 11791150. DOI: 10.1016/j.obpill.2025.100157.

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

Rodriguez P, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C JAMA Netw Open. 2025; 8(1):e2457349.

PMID: 39888616 PMC: 11786232. DOI: 10.1001/jamanetworkopen.2024.57349.

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.

DiStefano M, Dardouri M, Moore G, Saseen J, Nair K J Pharm Policy Pract. 2025; 18(1):2441220.

PMID: 39776466 PMC: 11703442. DOI: 10.1080/20523211.2024.2441220.

Anti-obesity medication patients' self-reported food savings versus the cost of such medicines.

Roe B Int J Obes (Lond). 2024; .

PMID: 39738491 DOI: 10.1038/s41366-024-01708-y.

Longitudinal policy surveillance of state obesity legislation in California, 1999-2020.

Payan D, Chan-Golston A, Garibay K, Farias C BMC Public Health. 2024; 24(1):3064.

PMID: 39508251 PMC: 11539810. DOI: 10.1186/s12889-024-20557-y.